ALLMedicine™ Acute Myeloid Leukemia Center
Research & Reviews 12,148 results
https://doi.org/10.1158/1078-0432.CCR-22-1598
Clinical Cancer Research : an Official Journal of the Ame... Gamlen HA, Romer-Seibert JS et. al.
Aug 10th, 2022 - DNMT3A mutations confer a poor prognosis in acute myeloid leukemia (AML), but the molecular mechanisms downstream of DNMT3A mutations in disease pathogenesis are not completely understood, limiting targeted therapeutic options. The role of microRN...
https://doi.org/10.1007/s12185-022-03427-4
International Journal of Hematology; Aydin S, Passera R et. al.
Aug 10th, 2022 - In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients ...
https://doi.org/10.1007/s10495-022-01756-7
Apoptosis : an International Journal on Programmed Cell D... Liu S, Qiao X et. al.
Aug 10th, 2022 - Acute myeloid leukemia (AML) is an aggressive disease with a low 5-year overall survival rate of 29.5%. Thus, more effective therapies are in need to prolong survival of AML patients. Mcl-1 is overexpressed in AML and is associated with poor progn...
https://doi.org/10.1016/j.blre.2022.100991
Blood Reviews; Serroukh Y, Hébert J et. al.
Aug 9th, 2022 - Acute myeloid leukemia (AML) is a cancer that originates from the bone marrow (BM). Under physiological conditions, the bone marrow supports the homeostasis of immune cells and hosts memory lymphoid cells. In this review, we summarize our present ...
https://doi.org/10.1038/s41467-022-32103-8
Nature Communications; Tazi Y, Arango-Ossa JE et. al.
Aug 9th, 2022 - Clinical recommendations for Acute Myeloid Leukemia (AML) classification and risk-stratification remain heavily reliant on cytogenetic findings at diagnosis, which are present in <50% of patients. Using comprehensive molecular profiling data from ...
Guidelines 12 results
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.
Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.
Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499615
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.
May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.
Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...
Drugs 30 results see all →
Clinicaltrials.gov 1,694 results
https://clinicaltrials.gov/ct2/show/NCT02688140
Aug 5th, 2022 - Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the...
https://clinicaltrials.gov/ct2/show/NCT02773732
Aug 5th, 2022 - This study will look at: any side effects that occur, the effectiveness of the study drug, and how your disease reacts to ciprofloxacin in combination with etoposide. This study will try to find the highest tolerated dose of ciprofloxacin without ...
https://clinicaltrials.gov/ct2/show/NCT04628338
Aug 5th, 2022 - Allogeneic hematopoietic stem cell transplantation (alloSCT) can cure patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, relapsed AML/MDS is the most significant single cause of treatment failure, and the major...
https://clinicaltrials.gov/ct2/show/NCT05028751
Aug 5th, 2022 - The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leu...
https://clinicaltrials.gov/ct2/show/NCT04161885
Aug 5th, 2022 - The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as mai...
News 1,655 results
https://www.medscape.com/viewarticle/964537
Jul 20th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York City. It is my t...
https://www.medscape.com/viewarticle/976987
Jul 12th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Low serum albumin is significantly associated with 60-day mortality in primary acute myeloid leukemia (AML). Why T...
https://www.medscape.com/viewarticle/976065
Jun 23rd, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Regarding consolidation therapy for younger patients with acute myeloid leukemia (AML), there was no survival benefit from taking high-dos...
https://www.medscape.com/viewarticle/964535
Jun 16th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, I'm a professor of medicine. I run the leukemia program at Weill Cornell Medicine at the NewYork-Presbyterian Hospital in New York City. It is ...
https://www.medscape.com/viewarticle/975457
Jun 13th, 2022 - The potent oral FLT3 inhibitor quizartinib more than doubled overall survival among patients newly diagnosed with FLT3-ITD-positive acute myeloid leukemia (AML) compared with standard chemotherapy, new phase 3 data show. Among adults who received ...